tag:blogger.com,1999:blog-8374717725359458448.comments2014-04-21T20:03:08.168-07:00Biotech MarketerAnonymoushttp://www.blogger.com/profile/08590569202982138251noreply@blogger.comBlogger31125tag:blogger.com,1999:blog-8374717725359458448.post-13967429322460441692013-05-16T23:14:36.884-07:002013-05-16T23:14:36.884-07:00Ethan, until they actually launch a product, it wi...Ethan, until they actually launch a product, it will be hard to know where ONT fits. However, it's looking more and more like it might be as a niche player (sort of like PacBio) rather than as an "Illumina killer" as people were calling them two years ago. Despite their delays I, and many others, am anxiously waiting to see what they can do.Anonymoushttps://www.blogger.com/profile/08590569202982138251noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-85462778572876147702013-05-16T20:11:21.202-07:002013-05-16T20:11:21.202-07:00I guess I'm Reader #4!
Thanks for the informa...I guess I'm Reader #4!<br /><br />Thanks for the informative post. Where does Oxford Nanopore fit into the landscape?Ethan Perlstein (@eperlste)http://perlsteinlab.comnoreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-54157198394490349292012-09-20T09:38:26.437-07:002012-09-20T09:38:26.437-07:00Another company might just announce $1000 genome o...Another company might just announce $1000 genome or less @ AGBT13 in Feb as in "ready to use". Perhaps BGI is upto something with Complete Genomics as we're talking..Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-87831626340765447732012-04-23T20:03:43.007-07:002012-04-23T20:03:43.007-07:00Yeah, a little pruning probably wouldn't hurt,...Yeah, a little pruning probably wouldn't hurt, but I've not been that 'bold'. Does LinkedIn send a message to the 'unfollowed' contact?Anonymoushttps://www.blogger.com/profile/08590569202982138251noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-90711538096822521322012-04-23T17:20:07.047-07:002012-04-23T17:20:07.047-07:00Totally agree on both points. In addition to being...Totally agree on both points. In addition to being picky with invitations, I've started pruning accepted contacts that really aren't strong. After years of growth, my number of LinkedIn connections is declining, and that's a good thing.TimmyGhttps://www.blogger.com/profile/06671327169007709869noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-2624778518157138622011-12-23T17:19:47.844-08:002011-12-23T17:19:47.844-08:00Thanks, Paul. It's my intention to update it e...Thanks, Paul. It's my intention to update it every once in a while. Monthly may be a little too frequent - I was thinking of once a quarter (Hmm, looks like even by that criterion I'm due - maybe I'll have a look at it over the break).<br /><br />There's lots of other 'in development' systems that could be added (Genia, NobleGen, Stratos, NABsys, LaserGen, IBS, Halcyon, ZS Genetics, Lightspeed, IBM/Roche, Electron Optica, others?). However, there's so little info about them that they're kind of hard to rate. Are there some systems that you think should definitely be on there?<br /><br />Not sure how to add anonymous comments to the table, but people are free to post down here. I even let the crackpot ones through ;-)Anonymoushttps://www.blogger.com/profile/08590569202982138251noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-40518670726698675242011-12-23T14:38:20.943-08:002011-12-23T14:38:20.943-08:00Pretty good arrow pointing for three months ago. Y...Pretty good arrow pointing for three months ago. You need to update this every month and add all the instruments that are missing and maybe add a second column with another graphic maybe including a tombstone. If you also added an anonymous way for commenters to add in their two cents but then that would just invite marketing to astroturf.Paul T Morrisonhttps://www.blogger.com/profile/01812165959718025046noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-56587274117166255412011-10-20T12:51:53.478-07:002011-10-20T12:51:53.478-07:00Anonymous #2,
It's now been 'a couple of ...Anonymous #2,<br /><br />It's now been 'a couple of months'. Has the 'serious competitor' emerged yet? Is it GnuBIO, ONP, someone else? Or do we need to wait a bit longer?Anonymoushttps://www.blogger.com/profile/08590569202982138251noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-11418247065542501072011-09-30T18:04:06.331-07:002011-09-30T18:04:06.331-07:00Pretty certain it'll be the exonuclease approa...Pretty certain it'll be the exonuclease approach as it's their own technology, the one Illumina are invested in, and the more mature of the two. Strand sequencing is the product of the UCSC collaboration and was only published recently. Excited about it all myself - I have high hopes.Gavin Oliverhttps://www.blogger.com/profile/12046185747683711054noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-78967865645724241162011-09-30T17:59:19.334-07:002011-09-30T17:59:19.334-07:00Well, now that you've posted it here, literall...Well, now that you've posted it here, literally 10s of people will see it. I sure hope you don't get in trouble ;-) Seriously, I'm quite excited about the potential of ONP - can't wait to see it. Do you know if it will be strand sequencing or exonuclease sequencing that will be in early access this year?Anonymoushttps://www.blogger.com/profile/08590569202982138251noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-10782082558994080282011-09-30T17:48:10.420-07:002011-09-30T17:48:10.420-07:00I believe ONT will have release the Gridion on ear...I believe ONT will have release the Gridion on early access this year. That's what they told me - and they said it wasn't a secret so hopefully my comment is kosher :)Gavin Oliverhttps://www.blogger.com/profile/12046185747683711054noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-15031670497469111712011-09-30T17:44:26.928-07:002011-09-30T17:44:26.928-07:00Good question, Gavin. I don't have any details...Good question, Gavin. I don't have any details, but I suspect it may be a while. The promise of nanopore sequencing has been 'just around the corner' for years now. Here's hoping we see something soon!Anonymoushttps://www.blogger.com/profile/08590569202982138251noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-67434791290040625662011-09-30T16:48:18.565-07:002011-09-30T16:48:18.565-07:00How long til we hear more about IBM and the Roche/...How long til we hear more about IBM and the Roche/DNAe collaboration I wonder?Gavin Oliverhttps://www.blogger.com/profile/12046185747683711054noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-58255798570305500132011-08-18T04:20:56.233-07:002011-08-18T04:20:56.233-07:00Hi all
Just wait a couple of months and you will s...Hi all<br />Just wait a couple of months and you will see a serious competitor to this.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-69449055422118079262011-08-17T09:08:41.027-07:002011-08-17T09:08:41.027-07:00Keith - one more point: the table already accounts...Keith - one more point: the table already accounts for the smaller bead sizes/increased density. So, by mid-2013, even if they're at their maximum stated density, they'll either need to be close to 100% fill efficiency or at read lengths greater than 1kb. Or, they'll have increased the density or increased the chip size. They just didn't talk about that possibility in the Nature paper.Anonymoushttps://www.blogger.com/profile/08590569202982138251noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-52255887118536668782011-08-17T09:04:59.623-07:002011-08-17T09:04:59.623-07:00Keith, I agree with you completely. I didn't a...Keith, I agree with you completely. I didn't attempt to layout the exact upgrade path, but rather take a guess at what the performance might be at 6 month increments.<br /><br />The 100% fill efficiency is pretty unrealistic, but I was using those #s as a kind of shortcut. The real point is that it will have to be pretty high unless the read lengths will be significantly over 1kb.<br /><br />And, yes, everything occurs in too-large jumps. That's just me being lazy. Maybe I'll go back and try to smooth it out a bit.Anonymoushttps://www.blogger.com/profile/08590569202982138251noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-38324245407943010622011-08-17T07:15:40.328-07:002011-08-17T07:15:40.328-07:00I'd really question whether either fill effici...I'd really question whether either fill efficiency or live beads can be gotten to 100%, and even if it approaches these I would expect more of a step-wise / asymptotic approach.<br /><br />Similarly, I will be surprised if the jumps in read length in the future are quite as large, particularly with smaller bead sizes to support higher densities. Perhaps they will get up to 1Kb, but I'm guessing it will be in smaller steps.Keith Robisonhttps://www.blogger.com/profile/04765318239070312590noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-3033611514135452802011-08-15T14:25:15.701-07:002011-08-15T14:25:15.701-07:00You know this is irrelevant, cost of a genome coul...You know this is irrelevant, cost of a genome could be free today on a 10,000$ machine and it would drive Life Technologies directly to bankruptcy. The adoption will simply not follow this roadmap and if it did, clinical sequencing wouldn't be truly used routinely in 2013... You and I both know that dirty little secret.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-73777364663563314302011-06-13T08:15:40.677-07:002011-06-13T08:15:40.677-07:00Usually service providers 4-6 weeks queue just mea...Usually service providers 4-6 weeks queue just means: <br /><br />1- that they are waiting for other samples to fill up the plate or<br />2- that they are waiting for samples that were supposed to be delivered weeks before but were not because the user is late or messed up the samples (which adds problems to 1-) or<br />3- that the machine is broken (happens at least once - twice a year based on my experience w NGSequencers) or<br />4- that a previous run went bad .... which usually means they got a bad reagents' lot (happens more than twice a year) or<br />5- that they are re-sequencing / re preparing the libraries because 3 or 4 just happened. <br /><br />In my experience 30-40% of the delay is due to lack of samples to run (to fill up the plate), 30-40 % is due to unreliable reagents/machines (both on illumina, 454 and SOLiD) and the remaining 20% is due to unreliable users that are not able to provide the samples as requested (quantity, quality, timing etc..)Marconoreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-33314932982096821052011-06-09T21:32:16.267-07:002011-06-09T21:32:16.267-07:00Thanks for taking the time to reply. I've res...Thanks for taking the time to reply. I've responded over at my blog, http://blog.fejes.ca/?p=770#comment-1543<br /><br />I still have a few other questions about the BlueSEQ model. Please let me know if you might have some time to talk about this - I'd be happy to write a follow-up post to correct any mistakes I may have made.Anthony Fejeshttps://www.blogger.com/profile/06637120783340508940noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-56304353448319757692011-06-09T20:16:57.515-07:002011-06-09T20:16:57.515-07:00Where are these providers that don't have full...Where are these providers that don't have full queues? Pfizer tried to outsource some sequencing to a third party when our internal queues filled up: there were 4-6 week delays for sequencing at a third party company. The provider queues seem pretty full...Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-18699124730750107502011-04-13T23:34:33.751-07:002011-04-13T23:34:33.751-07:00@Nels: Right now it seems that the IT error rates ...@Nels: Right now it seems that the IT error rates aren't great. Not awful like PacBio, but not up to the level of the market leaders. They're making lots of claims about future improvements, so we'll have to see. One claim that has (nearly) come true is some fairly significant improvements on the sample prep side with the announcement of their One Touch System which streamlines (replaces?) emPCR. At the very least they're making lots of noise (and probably the focus of a number of competitor strategy meetings).Anonymoushttps://www.blogger.com/profile/08590569202982138251noreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-90839191192600570192011-04-04T11:36:14.665-07:002011-04-04T11:36:14.665-07:00Do they really need a commercial? Are they short o...Do they really need a commercial? Are they short on branding?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-25649327072124979902011-04-02T13:35:15.612-07:002011-04-02T13:35:15.612-07:00Cool but I wouldn't say pointless at all. Ther...Cool but I wouldn't say pointless at all. There was plenty of symbolism in addition to the obvious "alter your sequencing reality" through use of cool tilt shift photography. So I'd say it's a fresh welcome to an otherwise dry industry. Working in biotech marketing, you have to give it that.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-8374717725359458448.post-7646785974766428182011-04-02T10:23:14.739-07:002011-04-02T10:23:14.739-07:00S-
What a hoot.
N-S-<br />What a hoot.<br />N-Unknownhttps://www.blogger.com/profile/01294681490656498025noreply@blogger.com